Viatris Connect

Efficacy & Tolerability

The data demonstrates that Creon® treats the symptoms of PEI and improves the nutritional status of patients with PEI and:

  • chronic pancreatitis1
  • pancreatic cancer1
  • cystic fibrosis2
  • diabetes3
  • coeliac disease1

In all associated diseases, Creon® has been shown to:1-3

  • increase fat absorption and reduce steatorrhoea
  • reduce stool frequency
  • improve stool consistency
  • be well tolerated

Creon® can achieve such improvements in patients with PEI because it has been developed to mimic the physiological pattern of pancreatic exocrine secretion.4


A review of data from 15,000 patients with PEI and cystic fibrosis, chronic pancreatitis or pancreatic cancer found that side effects were present in < 1% of patients. The most commonly reported adverse events were gastrointestinal disorders which are mainly associated with underlying disease. According to the Creon® SmPC, similar or lower incidences compared to placebo were reported for abdominal pain and diarrhoea.5-8


    1. Smith RC, Smith FS, Wilson J, Pearce C, Wray N, Vo R, et al. Australasian Pancreatic Club. Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology. October 2015 pp 1-1222
    2. Columbo C, et al. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas. 2009 Aug;38(6):693-699
    3. Mohan V, et al. Oral pancreatic enzyme therapy in the control of diabetes mellitus in tropical calculous pancreatitis. Int J Pancreatol. 1998; 24(1):19-22
    4. Domínguez-Muñoz JE et al. Advances in medical sciences, Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency: when is it indicated, what is the goal and how to do it? Vol.56(1), 2011, pp1-5
    5. Creon® Micro Summary of Product Characteristics. Available at: Last accessed: December 2023
    6. Creon® 10000 Summary of Product Characteristics. Available at: Last accessed: December 2023
    7. Creon® 25000 Summary of Product Characteristics. Available at: Last accessed: December 2023
    8. Imrie CW, et al. Review article: enzyme supplementation in cystic fibrosis, chronic pancreatitis, pancreatic and periampullary cancer. Aliment Pharmacol Ther. 2010; 1:1-25.

Guideline Recommendation

… the cornerstone of therapy for PEI is replacement of pancreatic enzymes to allow for efficient digestion and nutrient absorption.4

You will now leave the Creon patient website and go to the Creon Track site where you can join the Creon Track patient support programme

Would you like to proceed to the Creon Track registration website?


Viatris Connect is an online platform for UK healthcare professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.